Finasteride Cost in Maryland 2026

What Does Finasteride Actually Cost in Maryland?

Generic finasteride runs about $12 per month at Maryland retail pharmacies in 2026 when you use a discount card such as GoodRx or RxSaver. That figure reflects a 30-tablet supply of 1 mg tablets. The branded version, Propecia, carries a manufacturer list price near $85 per month, but almost no cash-pay patient needs to pay that.

Price depends heavily on which tool you use and which pharmacy you walk into. A quick price check across Baltimore, Rockville, and Annapolis locations in early 2026 shows CVS, Walgreens, and Walmart Pharmacy all dispense generic finasteride 1 mg for between $10 and $14 per month when a free discount coupon is applied at checkout. Costco Pharmacy, which is open to non-members for prescriptions in Maryland, regularly prices 30 tablets below $10.

The 5 mg tablet used for benign prostatic hyperplasia (BPH) follows a similar pattern. Generic finasteride 5 mg costs approximately $15 to $18 per month cash pay at most Maryland chains in 2026. Splitting a 5 mg tablet to approximate the 1 mg androgenetic alopecia (AGA) dose is a practice some clinicians discuss with patients, though it requires a prescriber's explicit direction and introduces dosing variability. The FDA label for finasteride 5 mg (Proscar) and 1 mg (Propecia) are separate approvals with separate indications. [1]

Finasteride is a 5-alpha-reductase type II inhibitor. It blocks the conversion of testosterone to dihydrotestosterone (DHT), the androgen primarily responsible for miniaturizing hair follicles in AGA and for driving prostatic growth in BPH. [2] That single mechanism explains its dual FDA-approved uses and why dosing differs between conditions.

How Does Maryland Medicaid Cover Finasteride?

Maryland Medicaid (HealthChoice) covers finasteride for both AGA and BPH, but requires prior authorization (PA) in both cases. The PA process asks the prescriber to document the diagnosis, confirm the patient has tried or is contraindicated to first-line alternatives where applicable, and submit clinical notes supporting medical necessity.

For BPH, the medical necessity argument is straightforward. The American Urological Association (AUA) guideline lists 5-alpha-reductase inhibitors, including finasteride, as appropriate pharmacotherapy for BPH with an enlarged prostate. [3] A urologist or primary care physician can typically secure PA approval within two to five business days by citing the AUA guideline language alongside prostate volume or symptom score data.

AGA presents a more involved PA pathway under Maryland Medicaid. Medicaid programs nationally have historically classified AGA treatment as cosmetic, but Maryland HealthChoice does maintain a pathway for coverage when a provider documents that hair loss is causing documented psychological or functional impairment. Dermatologists and psychiatrists familiar with the HealthChoice formulary can strengthen PA applications by referencing the demonstrated clinical efficacy from Kaufman et al. [4], which enrolled 1,553 men and showed that finasteride 1 mg daily produced visible hair regrowth or halted progression in 83% of participants at 24 months compared to 28% on placebo (P<0.001). [4]

Patients on Maryland Medicaid who are approved will generally pay a nominal co-pay of $1 to $3 per month for a generic drug in the lowest formulary tier. That makes approved Medicaid coverage the single cheapest route to finasteride in Maryland.

Dual-eligible beneficiaries (Medicare and Medicaid) should note that Medicare Part D covers finasteride for BPH in most plans but typically excludes it for AGA because AGA does not meet Part D's definition of a medically necessary condition under the current CMS guidelines. [5]

Is Compounded Finasteride Legal in Maryland?

Yes. Compounded finasteride is legal in Maryland when prepared by a licensed 503A pharmacy operating under state Board of Pharmacy oversight and federal USP compounding standards. [6]

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that dispense patient-specific prescriptions. [7] Maryland pharmacies operating under 503A are permitted to compound finasteride when a licensed prescriber issues a valid, patient-specific prescription, and when the compound is not a copy of a commercially available FDA-approved product without a clinical rationale. Because the commercially available formulations are oral tablets, compounding pharmacies in Maryland most commonly prepare finasteride as a topical solution (often 0.1% to 0.25% finasteride in a hydroalcoholic base) or in combination with minoxidil. These alternative delivery forms provide the clinical rationale needed to distinguish the compound from the commercially available tablets.

Compounded finasteride in Maryland costs approximately $45 per month in 2026, compared to $12 for generic oral tablets. The price difference reflects pharmacy compounding labor, specialized formulation, and the patient-specific nature of the dispensing process. Whether the higher cost is justified depends on whether the prescribing clinician believes a topical or novel-delivery formulation is clinically appropriate for a specific patient.

Maryland's Board of Pharmacy maintains a public license-verification tool. Patients should confirm any compounding pharmacy they use holds an active Maryland license and, if the pharmacy is based out of state, holds a non-resident pharmacy permit from Maryland. [8]

503B outsourcing facilities, which produce larger batches without patient-specific prescriptions, operate under FDA oversight rather than state pharmacy boards. [7] Currently, finasteride is not on the FDA's 503B bulk drug substances list, so Maryland patients receiving compounded finasteride should be receiving it from a 503A pharmacy with a valid individual prescription.

Which Insurance Plans Cover Finasteride in Maryland?

Private insurance coverage for finasteride in Maryland varies substantially by plan, diagnosis, and formulary year. For BPH, most commercial plans, including CareFirst BlueCross BlueShield of Maryland, Aetna Maryland, UnitedHealthcare, and Cigna, cover generic finasteride 5 mg as a Tier 1 or Tier 2 generic. Typical commercial co-pays run $5 to $15 per 30-day supply after the deductible is met, though high-deductible health plans (HDHPs) may require full generic cost until the deductible clears.

For AGA, coverage is inconsistent. Plans regulated under the Affordable Care Act's essential health benefits framework are not required to cover medications for conditions classified as cosmetic. Some Maryland ACA marketplace plans, particularly those with strong dermatology benefits, do cover finasteride 1 mg for AGA at Tier 1 or Tier 2 pricing. Others exclude it entirely. The only reliable way to verify coverage before filling is to call the member services number on your insurance card and ask specifically: "Does my plan cover finasteride 1 mg for androgenetic alopecia, and is it subject to prior authorization?"

Employer-sponsored plans operating as self-insured plans (governed by ERISA rather than Maryland state insurance law) set their own formularies. Large Maryland employers such as government agencies, universities, and hospital systems often negotiate broader formularies that include finasteride for AGA without PA. Federal Employee Health Benefits (FEHB) plans available to Maryland federal workers vary by carrier but generally cover finasteride for BPH; coverage for AGA requires plan-specific verification.

The Maryland Insurance Administration (MIA) can assist residents who believe they have been wrongly denied coverage. [9] If an insurer denies finasteride for BPH on medical necessity grounds, the AUA guideline provides strong grounds for an internal appeal. [3]

What Is the Cheapest Way to Get Finasteride in Maryland?

For most Maryland residents without Medicaid approval, generic finasteride at a discount-card price is the lowest-cost option at approximately $12 per month. Several specific strategies reduce costs further.

GoodRx Gold membership ($9.99/month per household) unlocks prices as low as $6 to $8 per month for generic finasteride 1 mg at select Maryland pharmacies. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists generic finasteride 1 mg at $4.20 for 30 tablets as of early 2026 and ships to Maryland. [10] That is currently the lowest publicly posted price for oral finasteride available to Maryland residents, though shipping time and mail-order convenience differ from local pharmacy pickup.

The Merck Patient Assistance Program (PAP) provides Propecia at no cost to patients who meet income eligibility criteria, generally at or below 200% to 400% of the federal poverty level. [11] The application requires a prescriber's signature and income verification. Approval typically takes two to four weeks. Merck's savings card for commercially insured patients reduces Propecia cost to $30 per month for eligible patients, but this card is not valid for Medicaid or Medicare beneficiaries.

The HealthRX Maryland Cost Ladder for finasteride in 2026, from lowest to highest monthly cost:

1. Cost Plus Drugs mail order: ~$4/month
2. GoodRx Gold at Walmart Pharmacy: ~$6 to $8/month
3. Standard GoodRx/RxSaver coupon at retail: ~$10 to $14/month
4. Maryland Medicaid (approved PA): ~$1 to $3 co-pay/month
5. Commercial insurance Tier 1 (BPH): ~$5 to $15 co-pay/month
6. Compounded topical (503A): ~$45/month
7. Branded Propecia cash pay: ~$85/month

The Medicaid co-pay sits lowest on a per-dollar basis but requires clearing the PA process first, which adds two to ten business days before the first fill.

Can You Get Finasteride via Telehealth in Maryland?

Yes. Maryland law permits telehealth prescribing of finasteride by licensed Maryland prescribers, including physicians, nurse practitioners, and physician assistants. The Maryland Department of Health's telehealth regulations do not require an in-person visit before prescribing finasteride for AGA or BPH, provided the clinician performs an adequate assessment and documents clinical findings consistent with the diagnosis. [12]

A synchronous audio-video consultation satisfies Maryland's telehealth standard of care requirements for most prescribers. Some telehealth platforms also offer asynchronous (store-and-forward) workflows where the patient completes a written intake with photos; Maryland's telehealth statute permits asynchronous prescribing in specific circumstances, and several platforms operating in Maryland use this model for AGA. Prescribers on those platforms should verify that their individual malpractice carrier and DEA registration support asynchronous prescribing.

Telehealth platforms such as Keeps, Hims, and HealthRX that operate in Maryland typically charge a monthly subscription fee that bundles the clinical visit and the prescription. Prices for these bundles range from $22 to $45 per month in 2026, which is higher than pharmacy-only cash pay but includes the prescriber visit, follow-up messaging, and sometimes additional hair-loss products.

Patients already diagnosed with AGA or BPH by an in-person provider can often transition to telehealth for refills. Maryland law allows telehealth prescribers to prescribe without a prior in-person relationship when the clinical situation does not require physical examination findings that cannot be assessed remotely. AGA, whose diagnosis relies primarily on pattern recognition and patient history, generally meets that threshold.

What Does the Clinical Evidence Say About Finasteride Efficacy?

Efficacy data supports the cost of finasteride regardless of which pricing tier a Maryland patient uses. Kaufman et al. (J Am Acad Dermatol, 1998, N=1,553) remains the definitive AGA trial. [4] Finasteride 1 mg daily halted hair loss in 83% of men and produced visible hair regrowth in 66% at 24 months, compared to 28% for placebo (P<0.001). Hair count data from standardized photographs showed a mean increase of 107 hairs per square centimeter in the finasteride group versus a decrease of 75 hairs per square centimeter in the placebo group. [4]

The drug's mechanism is well-characterized. Finasteride selectively inhibits 5-alpha-reductase type II, reducing serum DHT by approximately 70% at the 1 mg dose and approximately 65 to 70% at the 5 mg dose. [2] Scalp DHT falls even more sharply, by roughly 60 to 75%, which is the mechanism linking DHT suppression to follicle preservation.

Long-term data from the Prostate Cancer Prevention Trial (PCPT, N=18,882) showed that finasteride 5 mg daily over seven years reduced prostate cancer incidence by 24.8% compared to placebo. [13] The trial also identified a slightly higher frequency of high-grade prostate cancer in the finasteride arm, a finding that the FDA addressed in a 2011 label update requiring a class-wide warning for 5-alpha-reductase inhibitors. [1] Patients using finasteride 5 mg for BPH should have a baseline PSA drawn and should understand that finasteride lowers PSA values by approximately 50% after 6 to 12 months, which requires doubling the measured PSA to estimate true prostate cancer risk during monitoring. [14]

The Endocrine Society's clinical practice guideline on transgender care also recognizes finasteride's DHT-suppressing properties, citing its use in gender-affirming protocols, which reflects its growing off-label use beyond AGA and BPH. [15]

Sexual side effects, including decreased libido, erectile dysfunction, and reduced ejaculate volume, occur in approximately 1.4 to 3.8% of men in clinical trials at the 1 mg dose. [4] Post-marketing reports describe persistent sexual dysfunction in a subset of patients after discontinuation, a syndrome sometimes called post-finasteride syndrome, though its prevalence and mechanism remain under active investigation. [16] Prescribers in Maryland should document this risk discussion before initiating therapy.

Maryland-Specific Resources for Finasteride Access

Maryland residents have several state-specific resources beyond standard pharmacy channels. The Maryland Rx program (Maryland's state pharmaceutical assistance program) focuses primarily on seniors and individuals with disabilities; finasteride for AGA does not currently qualify, but finasteride for BPH may qualify for participants meeting income criteria. [17]

The Maryland Board of Pharmacy's license lookup confirms whether a specific pharmacy holds an active retail or non-resident dispensing license. Patients ordering from out-of-state telehealth pharmacies should use this tool. [8]

Community health centers funded under the Health Resources and Services Administration (HRSA) 340B program operate throughout Maryland, including sites in Baltimore City, Prince George's County, and Montgomery County. 340B pricing reduces drug acquisition costs dramatically for qualifying patients at participating sites; finasteride 1 mg at a 340B-participating clinic may cost under $5 per month even without a discount card. [18]

The Maryland Health Connection (the state's ACA marketplace) open enrollment runs November 1 through January 15 for coverage starting the following year. Residents who enroll in a silver or gold plan with CareFirst or Kaiser Permanente Mid-Atlantic should specifically ask the plan's pharmacy benefits team about finasteride AGA coverage before enrollment, as formulary details are not always prominent in plan summaries.